AI assistant
Sending…
REPLIGEN CORP — Director's Dealing 2018
Mar 6, 2018
30826_dirs_2018-03-05_49696f03-c93c-4001-83f6-64453f7bcc68.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2018-02-28
Reporting Person: KURIYEL RALF (Senior VP, R&D)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 5962 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $33.05 | 2026-12-14 | Common Stock (10000) | Direct |
Footnotes
F1: This option shall vest as follows: 2,000 shares shall vest on 12/14/2017; 12/14/2018; 12/14/2019; 12/14/2020 and on 12/14/2021.
More from REPLIGEN CORP
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 5
Proxy Solicitation & Information Statement
2026
Apr 27
Annual Report
2026
Apr 2
Proxy Solicitation & Information Statement
2026
Apr 2
Proxy Solicitation & Information Statement
2026
Apr 2
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 23
Director's Dealing
2026
Mar 23